Literature DB >> 20061858

Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis.

M-J Hallam1, J M Allen, S E James, P M W Donaldson, J G Davies, G W Hanlon, B S Dheansa.   

Abstract

Altered pharmacokinetics in patients with major burns may result in serum antibiotic concentrations below those required to be effective against the common pathogens encountered in burns patients. The major changes in the fluid volumes of key body compartments, which occur with a large burn, may increase the apparent volume of distribution of a drug, thereby lowering its concentration when a standard dose is given. In addition, the observed increase in renal blood flow reported in burns patients, because of the change in cardiac output, may result in a higher drug clearance and a shorter elimination half-life. As a consequence, studies have recommended higher doses or more frequent dosing or both for some antibiotics in patients with major burns, but data are lacking for many of the antibiotics reserved for treatment of life-threatening infections. The authors measured serum concentrations of two antibiotics, linezolid and meropenem, in an immunosuppressed patient who presented with a severe burn to determine whether therapeutic concentrations were achieved, thereby improving the likelihood of infection control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061858     DOI: 10.1097/BCR.0b013e3181c89ee3

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  7 in total

1.  Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".

Authors:  Laura Morata; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2013-12       Impact factor: 5.191

2.  Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.

Authors:  Alicia Galar; Maricela Valerio; Patricia Muñoz; Luis Alcalá; Xandra García-González; Almudena Burillo; María Sanjurjo; Santiago Grau; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.

Authors:  Federico Pea; Mario Furlanut; Piergiorgio Cojutti; Francesco Cristini; Eleonora Zamparini; Loretta Franceschi; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of Linezolid in burn patients.

Authors:  A Mokline; L Gharsallah; I Rahmani; E Gaies; S Tabelsi; A A Messadi
Journal:  Ann Burns Fire Disasters       Date:  2018-06-30

Review 5.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

6.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

7.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.

Authors:  Janie Faris; Ryan P Mynatt; Ashley D Hall Snyder; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2015-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.